CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
CRISPR Therapeutics AG
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for...
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
June 13, 2023 09:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
CRISPR Therapeutics AG
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- ...
CRISPR Therapeutics to Participate Upcoming Investor Conferences
May 02, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
April 13, 2023 16:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Announces Departure of Board Member
March 29, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
March 14, 2023 18:02 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Transition of Chief Financial Officer
March 13, 2023 16:15 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
February 27, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 21, 2023 16:01 ET
|
CRISPR Therapeutics AG
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing...